Category Archives: hypoactive sexual desire dysfunction HSDD

TGA accepts AndroFeme 1 for evaluation in postmenopausal women with Hypoactive Sexual Desire Dysfunction.

TGA accepts AndroFeme 1 for evaluation in postmenopausal women with HSDD. Perth, Western Australia; Dec. 05, 2019  — Lawley Pharmaceuticals today announced AndroFeme 1, … Continue reading

TGA accepts Lawley product for evaluation in postmenopausal women with HSDD.

TGA accepts Lawley product for evaluation in postmenopausal women with HSDD. Perth, Western Australia; Dec. 05, 2019  — Lawley Pharmaceuticals Pty Ltd today announced … Continue reading

Global Consensus Position Statement on the Use of Testosterone Therapy for Women

The Global Consensus Position Statement on the Use of Testosterone Therapy for Women was simultaneously published on the 2nd September 2019 in Maturitas, Journal … Continue reading